Neurology

Your Article Summary

See Latest Articles

Developments in the scientific and clinical understanding of fibromyalgia
Arthritis Research & Therapy, 10/16/09

Buskila D – The current concept views FM as the result of central nervous system malfunction resulting in amplification of pain transmission and interpretation. Research done over the past years has demonstrated a role for polymorphisms of genes in the serotoninergic, dopaminergic and catecholaminergic systems in the etiopathogenesis of FM. various external stimuli such as infection, trauma and stress may contribute to the development of the syndrome. The management of FM requires an integrated approach combining pharmacological and non – pharmacological modalities. The recent FDA approval of pregabalin, duloxetine and milnacipran as medications for FM may herald a new era for the development of medications with higher specificity and efficacy for the condition. As our understanding of the biological basis and the genetic underpinning of FM increases, the authors hope to gain a better understanding of the true nature of the disorder, better classify patients and attain more rational therapeutic modalities.

Today in Pain Medicine...keeping you current

Receive free subspecialty "5-minute updates" via email

Acute back pain: benefits and risks of current treatments
Current Medical Research and Opinion, 11/20/09

Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial
Diabetic Medicine, 10/01/09

Advances in fibromyalgia treatment: understanding endogenous pain modulation
International Journal of Clinical Rheumatology, 11/09/09

See All of Pain Medicine